spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Tourette Syndrome 

 HSMN NewsFeed - 3 Nov 2022
Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 27 Jan 2022
SciSparc Presents New Leadership Lineup
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 23 Mar 2021
Emalex Biosciences Raises $35 Million in Series C Preferred Stock to Advance Tourette Syndrome and Stuttering Clinical Trials
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 21 Dec 2018
Therapix Biosciences Terminates FSD Acquisition Letter of Intent
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 24 Jul 2018
AbbVie Receives U.S. FDA Approval of ORILISSA(TM) (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis
Biopharmaceuticals FDA Product Launch
 HSMN NewsFeed - 20 Mar 2018
Therapix Biosciences Announces FDA Clearance of Investigational New Drug (IND) for Phase IIa Clinical Trial of THX-110 in the Treatment of Chronic Low Back Pain
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Nov 2017
Therapix Biosciences' Board Chairman, Ascher Shmulewitz, Appointed as Interim Chief Executive Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 5 Oct 2017
Neurocrine Announces FDA Approval of 80 mg INGREZZA(R) (valbenazine) Capsules for the Treatment of Adults with Tardive Dyskinesia (TD)
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 18 Sep 2017
Abide Therapeutics Appoints Dr. Sapna Srivastava As Chief Financial and Strategy Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Apr 2017
Neurocrine Announces INGREZZA(TM) Long-Term Safety and Efficacy Data to be Presented at the 2017 American Academy of Neurology Annual Meeting
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Nov 2016
Neurocrine Announces FDA Advisory Committee Meeting to Review INGREZZA(TM) (valbenazine) New Drug Application for the Treatment of Tardive Dyskinesia
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 11 Oct 2016
Neurocrine Announces INGREZZA(TM) (valbenazine) New Drug Application for the Treatment of Tardive Dyskinesia has been Accepted for Priority Review by U.S. FDA
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 2 Feb 2016
Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Children and Adolescents with Tourette Syndrome
Biopharmaceuticals Neurology
 HSMN NewsFeed - 5 Jan 2015
Catalyst Pharmaceuticals Appoints David D. Muth, Executive Vice President, Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Sep 2014
Catalyst Pharmaceuticals Appoints David D. Muth as Executive Vice President, Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Mar 2014
Catalyst Pharmaceutical Partners Expands Executive Leadership Team to Support the Commercialization of Firdapse(TM)
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 8 Nov 2012
Auspex Pharmaceuticals Closes $25 Million Series D Financing
Biopharmaceuticals Neurology Venture Capital Personnel
 HSMN NewsFeed - 20 Jul 2009
Mylan Receives FDA Approval for Additional Strengths of the Antipsychotic Haloperidol
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 May 2009
Biovail Announces Acquisition of Worldwide Rights to Tetrabenazine
Biopharmaceuticals Neurology Acquisitions
Return to NewsFeed  

 Additional items found! 3

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 3 additional stories matching:
Tourette Syndrome
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.